Finding the Right CDMO Partner for Tech Transfer

20200921-EmergentCamden-0062-of-0101_3807-reduced

Regardless of where a drug candidate is in the development pipeline, performing a technology transfer (tech transfer) presents unique challenges for the partners involved.

Overcoming these challenges is critical to ensuring the ultimate success of the product when working with a Contract Development and Manufacturing Organization (CDMO). There are a myriad of ways in which a tech transfer can fail to meet its potential – unsatisfactory yields, unforeseen materials shortages, unoptimized batch sizes that can impact the quality and timelines of the transferred product.

Download our white paper to learn more about the challenges and opportunities of tech transfer, expedited tech transfer through bespoke approaches, choosing a CDMO for your tech transfer, and Emergent's value to partners. 

 

How CDMOs Can Support Nanoparticles for Gene Therapy, Immuno-Oncology and Vaccines

Nanoparticles have experienced increasing demand in recent years in biopharmaceutical formulations, owing to their utility for...

READ MORE

Streamlining Your Process Development Journey to GMP Manufacturing

Many CDMOs specialize in certain parts of the drug development lifecycle. Meanwhile, integrated turn-key offerings that support...

READ MORE

EXECUTIVE INTERVIEW – Emergent CDMO: A Molecule-to-Market Partner for Complex Biologics

For nearly 25 years, Emergent has developed, manufactured, and delivered their own innovative vaccines and biotherapeutic...

READ MORE